MedPath

STARS (Smoking Treatment And Remote Sampling) Study

Phase 1
Completed
Conditions
Cigarette Smoking
Smoking
Tobacco Smoking
Smoking Cessation
Interventions
Registration Number
NCT04525755
Lead Sponsor
Medical University of South Carolina
Brief Summary

This is a research study to find out if a smoking cessation medications, either varenicline or nicotine replacement products (patches or lozenges), are effective when given to smokers, remotely, as a one-time sample.

Participants will either receive a sample of varenicline, nicotine patches and lozenges, or neither. This will be decided randomly. Participants have a 50%chance of receiving varenicline, a 25% chance of receiving nicotine products, and a 25% chance of receiving neither. If the participant is assigned to a group that receives free samples, they will be mailed to them free of charge. There is no requirement to use them, and it is completely up to the participants. There is also no requirement to quit in this study.

The study lasts for six months, and will involve six total surveys. In addition, investigators ask that participants complete daily diaries (about 1 minute each) for the first 4 weeks of the study. Both varenicline and nicotine replacement products are well-established medications that help smokers quit.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
652
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Varenicline (.5mg BID)Varenicline 0.5 MGParticipants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline (.5 mg, 60 tablets total), NRT, or not, with outcomes assessed through 12 weeks of follow-up. 324 participants will be enrolled in this group. Participants in the varenicline sampling group will be given standard instructions on titration but ultimately will decide on their own as to if and how it is used. Dosing is lower than most industry trials of varenicline (1mg BID) but consistent with two trials of lower dosing that showed efficacy and with fewer side effects. Varenicline participants can choose to titrate 2mg if they wish, with shorter duration of sampling experience.
Nicotine Replacement Therapy (NRT)Nicotine Replacement Therapy (NRT)Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. 162 participants will be enrolled in this group. Participants in NRT group will receive 28 day supply of nicotine patch (1patch x 28 days @ 14mg) and lozenge (14 per day x 28 days @4mg) with instructions to use based on number of cigarettes smoked per day. Like varenicline participants, smokers in NRT group can use as much or as little of the NRT as they wish.
Primary Outcome Measures
NameTimeMethod
7-day Quit AttemptsFrom study enrollment through end of six-month follow up

Percentage of participants With 7-day self-reported point prevalence abstinence, among smokers randomized to a) varenicline, b) NRT, or c) no sampling control group

Secondary Outcome Measures
NameTimeMethod
Any Quit AttemptsFrom study enrollment through end of six-month follow up

Any self-defined attempt to stop smoking cigarettes among smokers randomized to a) varenicline, b) NRT, or c) no sampling control group

Use of Smoking Cessation MedicationFrom study enrollment through end of six-month follow up

Use of any smoking cessation medication among smokers randomized to a) varenicline, b) NRT, or c) no sampling control group

Reduction in SmokingAt the week 4 follow up and week 26 follow up.

Percentage of participants who have reduces their smoking by at least 50%, at both Week 4 and Week 26 follow-up, among smokers randomized to a) varenicline, b) NRT, or c) no sampling control group

Trial Locations

Locations (1)

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath